{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-025302","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.932918+00:00","generated_at":"2026-05-21T09:54:29.237704+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs","bullets":["Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).","Cash, equivalents, and marketable securities $220.6M; cash runway into 2027.","FHD-909 (SMARCA2 inhibitor) Phase 1 dose escalation in SMARCA4-mutated cancers ongoing, NSCLC primary target.","Selective CBP degrader targeting IND in 2026; ARID1B and EP300 degrader program updates expected H2 2025.","Board appointments: Neil Gallagher (Syndax President) and Stuart Duty (former Guggenheim Senior MD) in May 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-025302","json":"https://secwatch.observer/filing/0001628280-25-025302.json","markdown":"https://secwatch.observer/filing/0001628280-25-025302.md","text":"https://secwatch.observer/filing/0001628280-25-025302.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025025302/0001628280-25-025302-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025025302/fhtx-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:54:29.237704+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}